In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until ailment progression or perhaps the members are not able to tolerate the study drugs. Overall, our latest work highlights the potential utilization of ARV-825 in combination https://tommyk665whr8.p2blogs.com/profile